How it works
It binds cardiolipin in the inner mitochondrial membrane, which helps stabilize membrane structure, lower reactive oxygen species (ROS), and support sustained ATP (energy) production.
The evidence
Among mitochondrial peptides it has the strongest clinical data — Phase 2 and 3 trials in conditions like Barth syndrome, primary mitochondrial myopathy, and heart failure, plus a rare-disease designation. Results have been mixed across trials, which is itself informative.
Safety
As a compound studied under medical supervision, it has a developing safety profile from trials (injection-site reactions among reported effects). Research-chemical “SS-31” is not the trial product and carries the usual purity/identity uncertainty.
FAQ
Yes — elamipretide is the clinical name for SS-31.
No — it's investigational, having been through trials without full approval as of writing.
Sources
This profile summarizes the following. Follow the links to read the originals — and remember that summaries age, so check for newer information.
Inclusion here is not endorsement of any source's claims; several are cited so you can compare how different outlets characterize the same evidence.
Reviewed by Theo — part of the PepConnection crew.